Artwork

Content provided by U.S. Food, Drug Administration, and Center for Drug Evaluation. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by U.S. Food, Drug Administration, and Center for Drug Evaluation or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

FDA Drug Safety Podcast: FDA to evaluate potential risk of neural tube birth defects with HIV medicine dolutegravir (Juluca, Tivicay, Triumeq)

 
Share
 

Archived series ("Inactive feed" status)

When? This feed was archived on May 29, 2019 01:06 (5y ago). Last successful fetch was on April 17, 2019 13:20 (5y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Manage episode 206636821 series 1381764
Content provided by U.S. Food, Drug Administration, and Center for Drug Evaluation. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by U.S. Food, Drug Administration, and Center for Drug Evaluation or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
On May 18, 2018, FDA alerted the public that serious cases of neural tube birth defects involving the brain, spine, and spinal cord have been reported in babies born to women treated with dolutegravir used to treat human immunodeficiency virus (or HIV).
  continue reading

12 episodes

Artwork
iconShare
 

Archived series ("Inactive feed" status)

When? This feed was archived on May 29, 2019 01:06 (5y ago). Last successful fetch was on April 17, 2019 13:20 (5y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Manage episode 206636821 series 1381764
Content provided by U.S. Food, Drug Administration, and Center for Drug Evaluation. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by U.S. Food, Drug Administration, and Center for Drug Evaluation or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
On May 18, 2018, FDA alerted the public that serious cases of neural tube birth defects involving the brain, spine, and spinal cord have been reported in babies born to women treated with dolutegravir used to treat human immunodeficiency virus (or HIV).
  continue reading

12 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide